ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1820

Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active PsA in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

Philip Mease1, Atul Deodhar2, Désirée van der Heijde3, Frank Behrens4, Alan Kivitz5, Tom Lehman6, Lan Wei6, Marleen Nys7, Subhashis Banerjee6 and Miroslawa Nowak6, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2Oregon Health & Science University, Portland, OR, 3Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 4CIRI/Rheumatology and Fraunhofer Institute, Translational Medicine and Pharmacology ITMP, Goethe University, Frankfurt, Germany, 5Altoona Center for Clinical Research, Duncansville, PA, 6Bristol Myers Squibb, Princeton, NJ, 7Bristol Myers Squibb, Braine-l'Alleud, Belgium

Meeting: ACR Convergence 2021

Keywords: ACR 20, Deucravacitinib, Musculoskeletal, Psoriatic arthritis, TYK2 inhibitor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates IL-23, IL-12, and IFNα/β signaling. Deucravacitinib is a novel, oral selective inhibitor of TYK2 acting via the TYK2 regulatory domain. In a Phase 2 trial in patients with active PsA, the primary endpoint, ACR 20 response at Week (Wk) 16, was met and deucravacitinib was well tolerated versus placebo (PBO).1 This analysis further evaluated improvements in musculoskeletal disease manifestations in patients in the Phase 2 PsA trial.

Methods: This Phase 2 trial (NCT03881059) enrolled patients who had a PsA diagnosis for ≥6 months, fulfilled Classification Criteria for Psoriatic Arthritis, had active disease (≥3 tender joints, ≥3 swollen joints, CRP ≥3 mg/L), and had at least 1 active skin lesion. Patients either failed or were intolerant to ≥1 NSAID, corticosteroid, conventional synthetic DMARD, and/or 1 TNF inhibitor (TNFi; ≤30%). Patients were randomized 1:1:1 to deucravacitinib 6 mg QD or 12 mg QD or PBO, and stratified by TNFi status (experienced vs naive) and body weight (< 90 vs ≥90 kg). The current prespecified subgroup analysis assessed the likelihood of achieving ACR 20 response at Wk 16 based on study stratification factors. A post hoc analysis evaluated mean change from baseline (BL) to Wk 16 in ACR components (tender joint count, swollen joint count, Physician’s Global Assessment of PsA, Patients’ Global Assessment of disease activity, Patients’ Global Assessment of pain, high-sensitivity CRP [hCRP], and HAQ-DI score). Analyses were descriptive using data as observed.

Results: Of 203 patients randomized, 180 (89%) completed 16 wks of treatment (deucravacitinib 6 mg QD, 63/70 [90%]; deucravacitinib 12 mg QD, 59/67 [88%]; PBO, 58/66 [88%]). Demographic and BL disease characteristics were similar across groups. Mean age was 49.8 years and median PsA duration since diagnosis was 4.5 years. Patients treated with deucravacitinib were numerically more likely to achieve ACR 20 response at Wk 16 compared with PBO-treated patients regardless of TNFi experience or body weight, although some of these groups were small (Figure). Improvements for deucravacitinib 6 mg and 12 mg QD versus PBO were observed in all ACR components (Table), with apparent separation occurring as early as Wk 4 on, for example, HAQ-DI (mean change from BL, -0.2 vs -0.2 vs -0.1, respectively) and hCRP (mean change from BL, -7.4 vs -5.2 vs 0.3, respectively), and maintained through Wk 16. No serious adverse events, including serious infections, herpes zoster infection, opportunistic infections, malignancies, or thromboembolic events, were reported in any deucravacitinib treatment group.

Conclusion: Analyses confirmed the efficacy of deucravacitinib versus PBO across TNFi and body weight subgroups. With deucravacitinib treatment, improvements were displayed in all ACR components.

Reference: 1. Mease PJ et al. Presented at the 2020 ACR Convergence, American College of Rheumatology; Nov 5-9, 2020.


Disclosures: P. Mease, AbbVie, 2, 5, 6, Amgen, 2, 5, 6, Bristol-Myers Squibb, 2, 5, Eli Lilly, 2, 5, 6, Galapagos, 2, 5, Celgene, 2, Boehringer Ingelheim, 2, Genentech, 2, 5, 6, Janssen, 2, 5, 6, Gilead Sciences, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Sun Pharma, 2, 5, UCB Pharma, 2, 6, GSK, 2; A. Deodhar, Amgen, 2, Celgene, 2, Boehringer Ingelheim, 2, 12, Paid Instructor, AbbVie, 2, 5, Eli Lilly, 2, 5, Glaxo Smith & Kline, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, 6, 12, Paid Instructor, UCB, 2, 5, Janssen, 2, 6, Bristol-Myers Squibb, 2; D. van der Heijde, AbbVie, 2, Amgen, 2, Astellas, 2, AstraZeneca, 2, Bayer, 2, BMS, 2, Boehringer Ingelheim, 2, Celgene, 2, Cyxone, 2, Daiichi, 2, Eisai, 2, Eli Lilly, 2, Galapagos, 2, Gilead, 2, GlaxoSmithKline, 2, Janssen, 2, Merck, 2, Novartis, 2, Pfizer, 2, Regeneron, 2, Roche, 2, Sanofi, 2, Takeda, 2, UCB Pharma, 2, Imaging and Rheumatology BV, 4; F. Behrens, Pfizer, 2, 5, 6, Janssen, 5, Chugai, 2, 5, 6, Celgene, 2, 5, 6, Roche, 2, 5, AbbVie, 2, 6, Sanofi, 2, 6, Lilly, 2, 6, Novartis, 2, 6, Genzyme, 2, 6, Boehringer, 2, 6, Janssen, 2, 6, MSD, 2, 6, Bristol Myers Squibb, 2, 6, UCB Pharma, 2, 6; A. Kivitz, Pfizer, 2, 6, 11, 12, Sanofi, 2, 6, 11, 12, GlaxoSmithKline, 11, Gilead Sciences, Inc.,, 2, 11, Novartis, 2, 6, 12, AbbVie, 2, 6, 11, Boehringer Ingelheim, 2, Janssen, 2, Regeneron, 2, 6, 12, SUN Pharma Advanced Research, 2, Amgen, 11, Lilly, 6, Celgene, 6, 12, Flexion, 2, 6, Genzyme, 2, 6, 12, Merck, 6, 12, UCB, 6, Horizon, 6, 12; T. Lehman, Bristol Myers Squibb, 3, 11; L. Wei, Bristol Myers Squibb, 3, 11; M. Nys, Bristol Myers Squibb, 3, 11; S. Banerjee, Bristol Myers Squibb, 3, 11; M. Nowak, Bristol Myers Squibb, 3, 11.

To cite this abstract in AMA style:

Mease P, Deodhar A, van der Heijde D, Behrens F, Kivitz A, Lehman T, Wei L, Nys M, Banerjee S, Nowak M. Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active PsA in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/efficacy-of-deucravacitinib-an-oral-selective-tyrosine-kinase-2-inhibitor-in-musculoskeletal-manifestations-of-active-psa-in-a-phase-2-randomized-double-blind-placebo-controlled-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-deucravacitinib-an-oral-selective-tyrosine-kinase-2-inhibitor-in-musculoskeletal-manifestations-of-active-psa-in-a-phase-2-randomized-double-blind-placebo-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology